CicloMed
Private Company
Funding information not available
Overview
CicloMed LLC is a private, developmental-stage oncology company headquartered in Kansas City, USA, founded in 2006. Its core asset is Fosciclopirox, a prodrug of the antifungal agent ciclopirox, which is being repurposed as an intravesical and systemic therapy for bladder cancer, with ongoing Phase I clinical studies. The company emerged from a public-private partnership with The University of Kansas Cancer Center and is a portfolio company of BioNovus Innovations LLC, leveraging a team with deep expertise in drug development and oncology to address a significant unmet medical need.
Technology Platform
Prodrug platform based on ciclopirox, an antifungal agent repurposed as an anticancer therapeutic. The technology utilizes a phosphate prodrug (Fosciclopirox) to improve water solubility and enable intravenous or intravesical administration, which is then converted in vivo to the active drug.
Opportunities
Risk Factors
Competitive Landscape
The bladder cancer therapeutic landscape is evolving but has seen limited innovation for decades. Competition includes established intravesical agents (BCG, chemotherapy), newer systemic therapies like immune checkpoint inhibitors (e.g., pembrolizumab) and antibody-drug conjugates (e.g., enfortumab vedotin). CicloMed's novel mechanism and potential for intravesical use could differentiate it, but it must demonstrate superior efficacy or tolerability against these established and emerging options.